Ítem
Acceso Abierto

Tratamiento de Artritis reumatoide con antagonistas del factor de necrosis tumoral alfa y su asociación con el desarrollo de melanoma cutáneo: revisión sistemática de la literatura y meta-análisis.

Mostrar el registro sencillo de la publicación
dc.contributor.advisorCastellanos de la Hoz, Juan Camilo
dc.creatorAldana Silva, Carolina
dc.creatorChaparro Reyes, Laura
dc.creator.degreeEspecialista en Epidemiología (en Convenio con el CES)
dc.date.accessioned2015-06-09T18:47:11Z
dc.date.available2015-06-09T18:47:11Z
dc.date.created2015-05-22
dc.date.issued2015
dc.descriptionIntroducción: El tratamiento con antagonistas del factor de necrosis tumoral alfa (anti TNF) ha impactado el pronóstico y la calidad de vida de los pacientes con artritis reumatoide (AR) positivamente, sin embargo, se interroga un incremento en el riesgo de desarrollar melanoma. Objetivo: Conocer la asociación entre el uso de anti TNF y el desarrollo de melanoma maligno en pacientes con AR. Metodología: Se realizó una búsqueda sistemática en MEDLINE, EMBASE, COCHRANE LIBRARY y LILACS para ensayos clínicos, estudios observacionales, revisiones y meta-análisis en pacientes adultos con diagnóstico de AR y manejo con anti TNF (Certolizumab pegol, Adalimumab, Etanercept, Infliximab y Golimumab). Resultados: 37 estudios clínicos cumplieron los criterios de inclusión para el meta-análisis, con una población de 16567 pacientes. El análisis de heterogeneidad no fue significativo (p=1), no se encontró diferencia en el riesgo entre los grupos comparados DR -0.00 (IC 95% -0.001; -0.001). Un análisis adicional de los estudios en los que se reportó al menos 1 caso de melanoma (4222 pacientes) tampoco mostró diferencia en el riesgo DR -0.00 (IC 95% -0.004 ; -0.003). Conclusión: En la evidencia disponible a la fecha no encontramos asociación significativa entre el tratamiento con anti TNF en pacientes con diagnóstico de AR y el desarrollo de melanoma cutáneo.spa
dc.description.abstractIntroduction: Treatment with antagonists of the tumor necrosis factor alpha (anti- TNF) has impacted the prognosis and quality of life of patients with rheumatoid arthritis (RA) positively, however, there may be an incrased risk for cutaneous melanoma with this therapy. Objective: To determine the association between the use of anti- TNF and the development of malignant melanoma in patients with RA. Methods: A systematic search of MEDLINE, EMBASE, Cochrane Library and LILACS for clinical trials, observational studies, reviews and meta-analyzes in adult patients with RA diagnosis and management with anti TNF (certolizumab pegol, adalimumab, etanercept, infliximab and Golimumab) was performed. Results: 37 trials met the inclusion criteria for the meta-analysis, with a population of 16567 patients. The analysis of heterogeneity was not significant (p = 1), no difference was found in risk between the compared groups risk difference (RD) -0.00 (95% -0.001, -0.001). Further analysis of studies in which at least 1 case of melanoma (4222 patients) reported no difference in risk showed RD -0.00 (95% -0.004, -0.003). Conclusion: On the available evidence to date ther is no significant association between treatment with anti TNF and the development of cutaneous melanoma in patients with RA diagnosis.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.48713/10336_10526
dc.identifier.urihttp://repository.urosario.edu.co/handle/10336/10526
dc.language.isospa
dc.publisherUniversidad del Rosariospa
dc.publisher.departmentFacultad de medicinaspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto completo)spa
dc.rights.ccAtribución-SinDerivadas 2.5 Colombiaspa
dc.rights.ccAtribución-SinDerivadas 2.5 Colombiaspa
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.spa
dc.rights.urihttp://creativecommons.org/licenses/by-nd/2.5/co/
dc.source.bibliographicCitationAnuario estadístico 2010. Volúmen 8. Instituto Nacional de Cancerología 2012 kernel description. http://www.cancer.gov.co/contenido/contenido.aspx? catID=437&conID=747.
dc.source.bibliographicCitationCancer Incidence in Sweden 2005 kernel description. http://www. socialstyrelsen.se/Lists/Artikelkatalog/Attachments/9329/2007-42-3_ 2007423.pdf
dc.source.bibliographicCitationInformación sobre el cáncer para hombres kernel description. http://www.cancer.org/espanol/salud/guiasparaunavidasaludable/ informacion-sobre-el-cancer-para-hombres
dc.source.bibliographicCitationRiesgo de desarrollar cáncer de mama kernel description. http://www. breastcancer.org/es/sintomas/cancer_de_mama/riesgo/desarrollar
dc.source.bibliographicCitationTohru Abe, Tsutomu Takeuchi, Nobuyuki Miyasaka, Hiroshi Hashimoto, Hirobumi Kondo, Yoichi Ichikawa, y Ikuo Nagaya. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. The Journal of rheumatology, 33(1):37–44, 2006.
dc.source.bibliographicCitationÁlvaro Enrique Acosta, Eduardo Fierro, Victoria Eugenia Velásquez, y Xavier Rueda. Melanoma: patogénesis, clínica e histopatología. Asociación Colombiana de Dermatología y Cirugía Dermatológica, pág. 85, 2008.
dc.source.bibliographicCitationJoanne F Aitken, Andrew Barbour, Bryan Burmeister, Simon Taylor, Euan Walpole, Bernhard M Smithers, et al. Clinical practice guidelines for the management of melanoma in australia and new zealand. 2008.
dc.source.bibliographicCitationJuan-Manuel Anaya, Paula A Correa, Rub´en D Mantilla, Fabio Jimenez, Tamara Kuffner, y Janet M McNicholl. Rheumatoid arthritis in african colombians from quibdo. En Seminars in Arthritis and Rheumatism, tomo 31, p´ags. 191–198. Elsevier, 2001.
dc.source.bibliographicCitationFrank C Arnett, Steven M Edworthy, Daniel A Bloch, Dennis J McShane, James F Fries, Norman S Cooper, Louis A Healey, Stephen R Kaplan, Matthew H Liang, Harvinder S Luthra, et al. The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis & Rheumatism, 31(3):315–324, 1988.
dc.source.bibliographicCitationFabiola Atzeni, Marco Antivalle, Francesca Bobbio Pallavicini, Roberto Caporali, Chiara Bazzani, Roberto Gorla, Ennio Giulio Favalli, Antonio Marchesoni, y Piercarlo Sarzi-Puttini. Predicting response to anti-tnf treatment in rheumatoid arthritis patients. Autoimmunity reviews, 8(5):431–437, 2009.
dc.source.bibliographicCitationEva Baecklund, Christer Sundstr¨om, Anders Ekbom, Anca I Catrina, Peter Biberfeld, Nils Feltelius, y Lars Klareskog. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large b cell lymphoma. Arthritis & Rheumatism, 48(6):1543–1550, 2003.
dc.source.bibliographicCitationCarolina Barragán-Martínez, Jenny Amaya-Amaya, Ricardo Pineda-Tamayo, Rubén D Mantilla, Juan Castellanos-de la Hoz, Santiago Bernal-Macías, Adriana Rojas-Villarraga, y Juan-Manuel Anaya. Gender differences in latinamerican patients with rheumatoid arthritis. Gender medicine, 9(6):490–510, 2012.
dc.source.bibliographicCitationVictoria Bejarano, Mark Quinn, Philip G Conaghan, Richard Reece, Anne- Maree Keenan, David Walker, Andrew Gough, Michael Green, Dennis McGonagle, Ade Adebajo, Stephen Jarrett, Sheelagh Doherty, Lesley Hordon, Richard Melsom, Kristina Unnebrink, Hartmut Kupper, y Paul Emery. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis and rheumatism, 59(10):1467–74, 2008.
dc.source.bibliographicCitationTim Bongartz, Fiona C Warren, Daniel Mines, Eric L Matteson, Keith R Abrams, y Alex J Sutton. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Annals of the rheumatic diseases, 68(7):1177–1183, 2009.
dc.source.bibliographicCitationFerdinand C Breedveld, Michael H Weisman, Arthur F Kavanaugh, Stanley B Cohen, Karel Pavelka, Ronald van Vollenhoven, John Sharp, John L Perez, y George T Spencer-Green. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previo. Arthritis and rheumatism, 54(1):26–37, 2006.
dc.source.bibliographicCitationVivian P Bykerk, Pooneh Akhavan, Glen S Hazlewood, Orit Schieir, Anne Dooley, Boulos Haraoui, Majed Khraishi, Sharon A Leclercq, Jean L´egar´ e, Diane P Mosher, James Pencharz, Janet E Pope, John Thomson, Carter Thorne, Michel Zummer, y Claire Bombardier. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. The Journal of rheumatology, 39(8):1559–82, 2012.
dc.source.bibliographicCitationC Chabbert, H Adamski, G Guillet, B Sassolas, L Misery, A Perrinaud, L Machet, G Quereux, E Esteve, E Solau-Gervais, A Saraux, E Polard, T Lesimple, F Le Gall, B Dreno, y A Dupuy. Cutaneous melanoma in patients treated with tumour necrosis factor inhibitors: a retrospective series of 15 patients. Journal of the European Academy of Dermatology and Venereology : JEADV, 28(11):1540–4, 2014.
dc.source.bibliographicCitationEliza F Chakravarty y Evan R Farmer. Risk of skin cancer in the drug treatment of rheumatoid arthritis. Expert opinion on drug safety, 7(5):539–46, 2008.
dc.source.bibliographicCitationYen-Fu Chen, Paresh Jobanputra, Pelham Barton, SM Jowett, S Bryan, Wendy Clark, A Fry-Smith, y Amanda Burls. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health technology assessment, 10(42):1–266, 2006.
dc.source.bibliographicCitationE H S Choy, B Hazleman, M Smith, K Moss, L Lisi, D G I Scott, J Patel, M Sopwith, y D A Isenberg. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II doubleblinded, randomized, dose-escalating trial. Rheumatology (Oxford, England), 41(10):1133–7, 2002.
dc.source.bibliographicCitationErnest Choy, Frank McKenna, Jiri Vencovsky, Robert Valente, Niti Goel, Brenda Vanlunen, Owen Davies, Hans-Detlev Stahl, y Rieke Alten. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. Rheumatology (Oxford, England), 51(7):1226– 34, 2012.
dc.source.bibliographicCitationWen-Ming Chu. Tumor necrosis factor. Cancer letters, 328(2):222–225, 2013.
dc.source.bibliographicCitationDavid A Clark. Do anti-tnf-alfa drugs increase cancer risk in rheumatoid arthritis patients? Inflammopharmacology, 21(2):125–127, 2013.
dc.source.bibliographicCitationMarita Cross, Emma Smith, Damian Hoy, Loreto Carmona, Frederick Wolfe, Theo Vos, Benjamin Williams, Sherine Gabriel, Marissa Lassere, Nicole Johns, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Annals of the rheumatic diseases, 73(7):1316–1322, 2014.
dc.source.bibliographicCitationP Dewan, A Jawad, P Goldsmith, C Harwood, y R Cerio. Melanoma in patients with rheumatoid arthritis treated with antitumour necrosis factor: cause or coincidence? Report of two cases. The British journal of dermatology, 161(6):1412–4, 2009.
dc.source.bibliographicCitationTina Ding y Chris Deighton. Complications of anti-TNF therapies. Future Rheumatology, 2(6):587–597, 2007.
dc.source.bibliographicCitationWill Dixon y Alan Silman. Is there an association between anti-tnf monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? commentary on the meta-analysis by bongartz et al. Arthritis Research and Therapy, 8(5):111, 2006.
dc.source.bibliographicCitationPaul Emery, Ferdinand C Breedveld, Stephen Hall, Patrick Durez, David J Chang, Deborah Robertson, Amitabh Singh, Ronald D Pedersen, Andrew S Koenig, y Bruce Freundlich. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet, 372(9636):375–82, 2008.
dc.source.bibliographicCitationMartin Englund, Anna Jöud, Pierre Geborek, David T Felson, Lennart T Jacobsson, y Ingemar F Petersson. Prevalence and incidence of rheumatoid arthritis in southern sweden 2008 and their relation to prescribed biologics. Rheumatology, pág. keq127, 2010.
dc.source.bibliographicCitationRichard Essner. Surgical treatment of malignant melanoma. Surgical Clinics of North America, 83(1):109–156, 2003.
dc.source.bibliographicCitationGary S Firestein. Evolving concepts of rheumatoid arthritis. Nature, 423(6937):356–361, 2003.
dc.source.bibliographicCitationR Fleischmann, J Vencovsky, R F van Vollenhoven, D Borenstein, J Box, G Coteur, N Goel, H-P Brezinschek, A Innes, y V Strand. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Annals of the rheumatic diseases, 68(6):805–11, 2009.
dc.source.bibliographicCitationDaniel E Furst, Michael H Schiff, Roy M Fleischmann, Vibeke Strand, Charles A Birbara, Daniele Compagnone, Steven A Fischkoff, y Elliot K Chartash. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of star (safety trial of adalimumab in rheumatoid arthritis). The Journal of Rheumatology, 30(12):2563–2571, 2003.
dc.source.bibliographicCitationSara Gandini, Francesco Sera, Maria Sofia Cattaruzza, Paolo Pasquini, Roberto Zanetti, Cinzia Masini, Peter Boyle, y Carmelo Francesco Melchi. Metaanalysis of risk factors for cutaneous melanoma: Iii. family history, actinic damage and phenotypic factors. European Journal of Cancer, 41(14):2040–2059, 2005.
dc.source.bibliographicCitationKim Hø rslev Petersen, Merete Lund Hetland, Peter Junker, Jan Pø denphant, Torkell Ellingsen, Palle Ahlquist, Hanne Lindegaard, Asta Linauskas, Annette Schlemmer, Mette Yde Dam, Ib Hansen, Hans Christian Horn, Christian Gytz Ammitzbø ll, Anette Jø rgensen, Sophine B Krintel, Johnny Raun, Julia S Johansen, Mikkel Ø stergaard, y Kristian Stengaard-Pedersen. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, doubleblind,. Annals of the rheumatic diseases, 73(4):654–61, 2014.
dc.source.bibliographicCitationTakahiko Horiuchi, Hiroki Mitoma, Shin-ichi Harashima, Hiroshi Tsukamoto, y Terufumi Shimoda. Transmembrane tnf-alfa: structure, function and interaction with anti-tnf agents. Rheumatology, 49(7):1215–1228, 2010.
dc.source.bibliographicCitationAndrew Howe, Laura Ten Eyck, Robert Dufour, Neel Shah, y David J Harrison. Treatment patterns and annual drug costs of biologic therapies across indications from the humana commercial database. J Manag Care Pharm, 20(12):1236–44, 2014.
dc.source.bibliographicCitationKari Dolven Jacobsen, Sophie D Foss° a, y Steinar Aamdal. [Malignant melanoma–diagnosis and treatment]. Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række, 126(23):3094–7, 2006.
dc.source.bibliographicCitationA C Katoulis, A Kanelleas, G Zambacos, I Panayiotides, y N G Stavrianeas. Development of two primary malignant melanomas after treatment with adalimumab: a case report and review of the possible link between biological therapy with TNF-alpha antagonists and melanocytic proliferation. Dermatology (Basel, Switzerland), 221(1):9–12, 2010.
dc.source.bibliographicCitationJonathan Kay, Eric L Matteson, Bhaskar Dasgupta, Peter Nash, Patrick Durez, Stephen Hall, Elizabeth C Hsia, John Han, Carrie Wagner, Zhenhua Xu, Sudha Visvanathan, y Mahboob U Rahman. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis and rheumatism, 58(4):964–75, 2008.
dc.source.bibliographicCitationE C Keystone, M C Genovese, L Klareskog, E C Hsia, S T Hall, P C Miranda, J Pazdur, S-C Bae, W Palmer, J Zrubek, M Wiekowski, S Visvanathan, Z Wu, y M U Rahman. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Annals of the rheumatic diseases, 68(6):789–96, 2009.
dc.source.bibliographicCitationEdward Keystone, D´ esire ´e van der Heijde, David Mason, Robert Landew´ e, Ronald Van Vollenhoven, Bernard Combe, Paul Emery, Vibeke Strand, Philip Mease, Chintu Desai, y Karel Pavelka. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis and rheumatism, 58(11):3319–29, 2008.
dc.source.bibliographicCitationEdward C Keystone, Arthur F Kavanaugh, John T Sharp, Hyman Tannenbaum, Ye Hua, Leah S Teoh, Steven A Fischkoff, y Elliot K Chartash. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled. Arthritis and rheumatism, 50(5):1400–11, 2004.
dc.source.bibliographicCitationEdward C Keystone, Désirée van der Heijde, Arthur Kavanaugh, Hartmut Kupper, Shufang Liu, Benôıt Guérette, y Neelufar Mozaffarian. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis. The Journal of rheumatology, 40(9):1487–97, 2013.
dc.source.bibliographicCitationI Khan, L Rahman, y D B McKenna. Primary cutaneous melanoma: a complication of infliximab treatment? Clinical and experimental dermatology, 34(4):524– 6, 2009.
dc.source.bibliographicCitationHo-Youn KIM, Soo-Kon LEE, Yeong Wook SONG, Dae-Hyun YOO, Eun-Mi KOH, Bin YOO, y Allison LUO. A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. APLAR Journal of Rheumatology, 10(1):9–16, 2007.
dc.source.bibliographicCitationJoel Kremer, Christopher Ritchlin, Alan Mendelsohn, Daniel Baker, Lilianne Kim, Zhenhua Xu, John Han, y Peter Taylor. Golimumab, a new human antitumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis and rheumatism, 62(4):917–28, 2010.
dc.source.bibliographicCitationJerry SS LANCHBURY. Molecular genetics of the hla-d region component of inherited susceptibility to rheumatoid arthritis. Rheumatology, 27(3):171–175, 1988.
dc.source.bibliographicCitationPierre Le Blay, Gael Mouterde, Thomas Barnetche, Jacques Morel, y Bernard Combe. Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trials. The Journal of rheumatology, 39(4):712– 715, 2012.
dc.source.bibliographicCitationMaria A Lopez-Olivo, Jean H Tayar, Juan A Martinez-Lopez, Eduardo N Pollono, Jose Polo Cueto, M Rosa Gonzales-Crespo, Stephanie Fulton, y Maria E Suarez-Almazor. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. Jama, 308(9):898–908, 2012.
dc.source.bibliographicCitationDora I Loria, Abel González, y Clara Latorre. Epidemiología del melanoma cutáneo en argentina: análisis del registro argentino de melanoma cutáneo. Dermatología Argentina, 16(1):39–45, 2010.
dc.source.bibliographicCitationR N Maini, F C Breedveld, J R Kalden, J S Smolen, D Furst, M H Weisman, E W St Clair, G F Keenan, D van der Heijde, P A Marsters, y P E Lipsky. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis and rheumatism, 50(4):1051–65, 2004.
dc.source.bibliographicCitationAusilia Maria Manganoni, Cristina Zane, Laura Pavoni, Camillo Farisoglio, Elena Sereni, Piergiacomo Calzavara-Pinton, Manganoni Ausilia Maria, Zane Cristina, Pavoni Laura, Farisoglio Camillo, Sereni Elena, Calzavara-Pinton PierGiacomo, Ausilia Maria Manganoni, Cristina Zane, Laura Pavoni, Camillo Farisoglio, Elena Sereni, Piergiacomo Calzavara-Pinton, Manganoni Ausilia Maria, Zane Cristina, Pavoni Laura, Farisoglio Camillo, Sereni Elena, Calzavara-Pinton PierGiacomo, Ausilia Maria Manganoni, Cristina Zane, Laura Pavoni, Camillo Farisoglio, Elena Sereni, Piergiacomo Calzavara-Pinton, Manganoni Ausilia Maria, Zane Cristina, Pavoni Laura, Farisoglio Camillo, Sereni Elena, y Calzavara-Pinton PierGiacomo. Cutaneous melanoma in patients in treatment with biological therapy: review of the literature and case report. Dermatology online journal, 17(8):12, 2011.
dc.source.bibliographicCitationXavier Mariette, Marco Matucci-Cerinic, Karel Pavelka, Peter Taylor, Ronald van Vollenhoven, Rebecca Heatley, Claire Walsh, Richard Lawson, Alan Reynolds, y Paul Emery. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and metaanalysis. Annals of the rheumatic diseases, 70(11):1895–1904, 2011.
dc.source.bibliographicCitationIain B McInnes y Georg Schett. The pathogenesis of rheumatoid arthritis. New England Journal of Medicine, 365(23):2205–2219, 2011.
dc.source.bibliographicCitationPier-Luigi Meroni y Guido Valesini. Tumour necrosis factor alfa antagonists in the treatment of rheumatoid arthritis: an immunological perspective. BioDrugs, 28(1):5–13, 2014.
dc.source.bibliographicCitationKathrine Damm Meyle y Per Guldberg. Genetic risk factors for melanoma. Human genetics, 126(4):499–510, 2009.
dc.source.bibliographicCitationNobuyuki Miyasaka. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Modern rheumatology / the Japan Rheumatism Association, 18(3):252–62, 2008.
dc.source.bibliographicCitationEmilio Montserrat. Chronic lymphoproliferative disorders. Current opinion in oncology, 9(1):34–41, 1997.
dc.source.bibliographicCitationGuillaume Moulis, Agnès Sommet, Johana Béné, Francois Montastruc, Laurent Sailler, Jean-Louis Montastruc, y Maryse Lapeyre-Mestre. Cancer risk of antitnf-alfa at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. PLoS One, 7(11):e48991, 2012.
dc.source.bibliographicCitationB Nardone, J A Hammel, D W Raisch, L L Weaver, D Schneider, y D P West. Melanoma associated with tumour necrosis factor-↵ inhibitors: a Research on Adverse Drug events And Reports (RADAR) project. The British journal of dermatology, 170(5):1170–2, 2014.
dc.source.bibliographicCitationJohn Nova-Villanueva, Guillermo S´anchez-Vanegas, y Luisa Porras de Quintana. Skin cancer: a Colombian reference centre’s epidemiological profile 2003-2005. Rev Salud Publica (Bogota), págs. 595–601, 2007.
dc.source.bibliographicCitationMark A Quinn, Philip G Conaghan, Philip J O’Connor, Zunaid Karim, Adam Greenstein, Andrew Brown, Clare Brown, Alexander Fraser, Stephen Jarret, y Paul Emery. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-m. Arthritis and rheumatism, 52(1):27–35, 2005.
dc.source.bibliographicCitationR Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, 2014.
dc.source.bibliographicCitationPauline Raaschou, Julia F Simard, Marie Holmqvist, Johan Askling, et al. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from sweden. Bmj, 346, 2013.
dc.source.bibliographicCitationDean A Regier, Nick Bansback, Anne Dar Santos, y Carlo A Marra. Costeffectiveness of tumor necrosis factor-alfa antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. 2007.
dc.source.bibliographicCitationMichael Schiff, Michael E Weinblatt, Robert Valente, D´ esir ´ee van der Heijde, Gustavo Citera, Ayanbola Elegbe, Michael Maldonado, y Roy Fleischmann. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Annals of the rheumatic diseases, 73(1):86–94, 2014.
dc.source.bibliographicCitationRafael A Schmerling, Dora Loria, Gabriela Cinat, Wilmer E Ramos, Andr´es F Cardona, Jorge L S´anchez, Hector Martinez-Said, y Antonio C Buzaid. Cutaneous melanoma in latin america: the need for more data. Revista Panamericana de Salud P´ublica, 30(5):431–438, 2011.
dc.source.bibliographicCitationDL Scott, F Wolfe, y TW Huizinga. Rheumatoid arthritis. Lancet, 376(9746):1094–1108, 2010.
dc.source.bibliographicCitationXu Shengqian. Tnf inhibitor therapy for rheumatoid arthritis. 2012.
dc.source.bibliographicCitationScott A Siegel, David J Shealy, Marian T Nakada, Junming Le, Donna SWoulfe, Lesley Probert, George Kollias, John Ghrayeb, Jan Vilcek, y Peter E Daddona. The mouse/human chimeric monoclonal antibody ca2 neutralizes tnf in vitro and protects transgenic mice from cachexia and tnf lethality in vivo. Cytokine, 7(1):15–25, 1995.
dc.source.bibliographicCitationAllison L Smitten, Teresa A Simon, Marc C Hochberg, y Samy Suissa. A metaanalysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Research and Therapy, 10(2):R45, 2008.
dc.source.bibliographicCitationJ Smolen, R B Landew´ e, P Mease, J Brzezicki, D Mason, K Luijtens, R F van Vollenhoven, A Kavanaugh, M Schiff, G R Burmester, V Strand, J Vencovsky, y D van der Heijde. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Annals of the rheumatic diseases, 68(6):797–804, 2009.
dc.source.bibliographicCitationJosef S Smolen, Jonathan Kay, Mittie Doyle, Robert Landew´ e, Eric L Matteson, Norman Gaylis, J¨urgen Wollenhaupt, Frederick T Murphy, Stephen Xu, Yiying Zhou, y Elizabeth C Hsia. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor ¿ inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. Arthritis research & therapy, 17(1):14, 2015.
dc.source.bibliographicCitationJosef S Smolen, Jonathan Kay, Mittie K Doyle, Robert Landew´ e, Eric L Matteson, J¨urgen Wollenhaupt, Norman Gaylis, Frederick T Murphy, Jeffrey S Neal, Yiying Zhou, Sudha Visvanathan, Elizabeth C Hsia, Mahboob U Rahman, Smolen JS, Kay J, Doyle MK, Landew´e R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, y Rahman MU. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet, 374(9685):210– 21, 2009.
dc.source.bibliographicCitationJosef S Smolen, Peter Nash, Patrick Durez, Stephen Hall, Elena Ilivanova, Fedra Irazoque-Palazuelos, Pedro Miranda, Min-Chan Park, Karel Pavelka, Ronald Pedersen, Annette Szumski, Constance Hammond, Andrew S Koenig, y Bonnie Vlahos. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. The Lancet, 381(9870):918–929, 2013.
dc.source.bibliographicCitationDaniel H Solomon. The comparative safety and effectiveness of tnf-o antagonists. J Manag Care Pharm, 13(1):S7–S18, 2007.
dc.source.bibliographicCitationE William St Clair, D´ esir ´ee M F M van der Heijde, Josef S Smolen, Ravinder N Maini, Joan M Bathon, Paul Emery, Edward Keystone, Michael Schiff, Joachim R Kalden, Ben Wang, Kimberly Dewoody, Roberta Weiss, y Daniel Baker. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis and rheumatism, 50(11):3432– 43, 2004.
dc.source.bibliographicCitationJonathan AC Sterne y Matthias Egger. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. Journal of clinical epidemiology, 54(10):1046–1055, 2001.
dc.source.bibliographicCitationCiro Tetta, G Camussi, V Modena, C Di Vittorio, y C Baglioni. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Annals of the rheumatic diseases, 49(9):665–667, 1990.
dc.source.bibliographicCitationCarter Thorne, William G Bensen, Denis Choquette, Andrew Chow, Majed Khraishi, Christopher J Atkins, John T Kelsall, Allen J Lehman, May Shawi, Hayssam Khalil, et al. Effectiveness and safety of infliximab in rheumatoid arthritis: Analysis from a canadian multicenter prospective observational registry. Arthritis care & research, 66(8):1142–1151, 2014.
dc.source.bibliographicCitationGabriel J Tob´on, Pierre Youinou, y Alain Saraux. The environment, geoepidemiology, and autoimmune disease: rheumatoid arthritis. Journal of autoimmunity, 35(1):10–14, 2010.
dc.source.bibliographicCitationMargaret A Tucker. Melanoma epidemiology. Hematology/oncology clinics of North America, 23(3):383–395, 2009.
dc.source.bibliographicCitationClaire M Vajdic, Stephen P McDonald, Margaret RE McCredie, Marina T van Leeuwen, John H Stewart, Matthew Law, Jeremy R Chapman, Angela C Webster, John M Kaldor, y Andrew E Grulich. Cancer incidence before and after kidney transplantation. Jama, 296(23):2823–2831, 2006.
dc.source.bibliographicCitationL B A van de Putte, C Atkins, M Malaise, J Sany, A S Russell, P L C M van Riel, L Settas, J W Bijlsma, S Todesco, M Dougados, P Nash, P Emery, N Walter, M Kaul, S Fischkoff, y H Kupper. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Annals of the rheumatic diseases, 63(5):508–16, 2004.
dc.source.bibliographicCitationL B A van de Putte, R Rau, F C Breedveld, J R Kalden, M G Malaise, P L C M van Riel, M Schattenkirchner, P Emery, G R Burmester, H Zeidler, H M Moutsopoulos, K Beck, y H Kupper. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Annals of the rheumatic diseases, 62(12):1168–77, 2003.
dc.source.bibliographicCitationR F van Vollenhoven, S Ernestam, P Geborek, I F Petersson, L C¨ oster, E Waltbrand, A Zickert, J Theander, A Th¨ orner, H Hellstr ¨om, A Teleman, C Dackhammar, F Akre, K Forslind, L Ljung, R Oding, A Chatzidionysiou, M W¨ ornert, y J Bratt. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet, 374(9688):459– 66, 2009.
dc.source.bibliographicCitationWolfgang Viechtbauer. Conducting meta-analyses in R with the metafor package. Journal of Statistical Software, 36(3):1–48, 2010.
dc.source.bibliographicCitationJohn P Waters, Jordan S Pober, y John R Bradley. Tumour necrosis factor and cancer. The Journal of pathology, 230(3):241–248, 2013.
dc.source.bibliographicCitationM. E. Weinblatt, R. Fleischmann, T. W. J. Huizinga, P. Emery, J. Pope, E. M. Massarotti, R. F. van Vollenhoven, J. Wollenhaupt, C. O. Bingham, B. Duncan, N. Goel, O. R. Davies, y M. Dougados. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology, 51(12):2204–2214, 2012.
dc.source.bibliographicCitationM E Weinblatt, J M Kremer, A D Bankhurst, K J Bulpitt, R M Fleischmann, R I Fox, C G Jackson, M Lange, y D J Burge. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. The New England journal of medicine, 340(4):253–9, 1999.
dc.source.bibliographicCitationMichael E Weinblatt, Edward C Keystone, Daniel E Furst, Larry W Moreland, Michael H Weisman, Charles A Birbara, Leah A Teoh, Steven A Fischkoff, y Elliot K Chartash. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis and rheumatism, 48(1):35–45, 2003.
dc.source.bibliographicCitationRene Westhovens, David Yocum, John Han, Alberto Berman, Ingrid Strusberg, Piet Geusens, y Mahboob U Rahman. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities in a large, randomized, placebo-controlled trial. Arthritis and rheumatism, 54(4):1075–86, 2006.
dc.source.bibliographicCitationFrederick Wolfe y Kaleb Michaud. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis and rheumatism, 56(9):2886–95, 2007.
dc.source.bibliographicCitationKazuhiko Yamamoto, Tsutomu Takeuchi, Hisashi Yamanaka, Naoki Ishiguro, Yoshiya Tanaka, Katsumi Eguchi, Akira Watanabe, Hideki Origasa, Koichi Iwai, Yoshiharu Sakamaki, D´ esir ´ee van der Heijde, Nobuyuki Miyasaka, y Takao Koike. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial. Modern rheumatology / the Japan Rheumatism Association, 24(4):552–60, 2014.
dc.source.bibliographicCitationKazuhiko Yamamoto, Tsutomu Takeuchi, Hisashi Yamanaka, Naoki Ishiguro, Yoshiya Tanaka, Katsumi Eguchi, Akira Watanabe, Hideki Origasa, Toshiharu Shoji, Yoshiharu Sakamaki, D´ esir ´ee van der Heijde, Nobuyuki Miyasaka, y Takao Koike. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. Modern rheumatology / the Japan Rheumatism Association, 24(5):715–24, 2014.
dc.source.bibliographicCitationPhilippa Youl, Joanne Aitken, Nicholas Hayward, David Hogg, Ling Liu, Norman Lassam, Nicholas Martin, y Adele Green. Melanoma in adolescents: A casecontrol study of risk factors in queensland, australia. International journal of cancer, 98(1):92–98, 2002.
dc.source.bibliographicCitationGuillaume Moulis, Agnes Sommet, Francois Montastruc, Laurent Sailler, Jean- Louis Montastruc, y Maryse Lapeyre-Mestre. No increased malignancy risk in tumor necrosis factor-alpha antagonists treated adult rheumatoid arthritis patients: A meta-analysis of 29 randomized controlled trials. En ARTHRITIS AND RHEUMATISM, tomo 63, p´ags. S168–S169. WILEY-BLACKWELL COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA, 2011.
dc.source.bibliographicCitationN Laird y REBECCA DerSimonian. Issues in combining evidence from several comparative trials of clinical therapy. En Proceeding of the XIth International Biometric Conference, págs. 91–97. 1982.
dc.source.bibliographicCitationMichael J Bradburn, Jonathan J Deeks, Jesse A Berlin, y A Russell Localio. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Statistics in medicine, 26(1):53–77, 2007.
dc.source.bibliographicCitationSa¨ıd C Azoury y Julie R Lange. Epidemiology, risk factors, prevention, and early detection of melanoma. Surgical Clinics of North America, 94(5):945– 962, 2014.
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subjectAntagonista del factor de necrosis tumoral afaspa
dc.subjectAnti TNF alfaspa
dc.subjectEtanerceptspa
dc.subjectGolimumabspa
dc.subjectInfliximabspa
dc.subjectCertolizumabspa
dc.subjectAdalimumabspa
dc.subjectMelanoma cutáneospa
dc.subjectEvento adversospa
dc.subject.ddcEnfermedades
dc.subject.decsArtritis reumatoidespa
dc.subject.decsEpidemiologíaspa
dc.subject.decsArticulaciones - Enfermedadesspa
dc.subject.decsAdyuvantes Inmunológicosspa
dc.subject.keywordArtritis reumatoidespa
dc.subject.keywordTumor necrosis factor alfaeng
dc.subject.keywordTumor necrosis factor alfa antagonisteng
dc.subject.keywordAnti TNFeng
dc.subject.keywordCertolizumabeng
dc.subject.keywordAdalimumabeng
dc.subject.keywordEtanercepteng
dc.subject.keywordInfliximabeng
dc.subject.keywordGolimumabeng
dc.subject.keywordCutaneous melanomaeng
dc.subject.keywordadverse effectseng
dc.titleTratamiento de Artritis reumatoide con antagonistas del factor de necrosis tumoral alfa y su asociación con el desarrollo de melanoma cutáneo: revisión sistemática de la literatura y meta-análisis.spa
dc.typebachelorThesiseng
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.type.spaTrabajo de gradospa
Archivos
Bloque original
Mostrando1 - 2 de 2
Miniatura
Nombre:
ChaparroReyes-Laura-2015.pdf
Tamaño:
928.94 KB
Formato:
Adobe Portable Document Format
Descripción:
Tesis
Descargar
Miniatura
Nombre:
ChaparroReyes-Laura-2015.pdf
Tamaño:
2.37 MB
Formato:
Adobe Portable Document Format
Descripción:
Presentación Tesis
Descargar
Colecciones
Especialización en Epidemiología